Minerva Neurosciences Inc NERV shares are trading higher by $1.60 (15 percent) at $13.90 in Wednesday's session. It has backed off its intra-day and all-time high made earlier in the session at $14.54.
The issue continues to benefit from meeting primary and secondary endpoints for MIN-101 Monotherapy. Since making the announcement on May 25, the issue has added over $10, or over 300 percent, since its May 25 close of $3.54.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in